Results 51 to 60 of about 88,938 (144)

Elderly age group patients with COPD continuing to smoke -a problem that cannot be ignored

Medicine in Drug Discovery, 2020
Introduction: According to the WHO, 30.9% of the adult population of the Russian Federation are active smokers. From 30% to 43% of smoking patients with COPD are not able to give up nicotine despite the diagnosis and deterioration of health.
Vitalii I. Kupaev, Dmitriy A. Osipov
doaj   +1 more source

2025 Consensus Clinical Management Guidelines for Niemann‐Pick Disease Type C

Journal of Inherited Metabolic Disease, Volume 49, Issue 3, May 2026.
ABSTRACT In 2018, the International Niemann‐Pick Disease Alliance (INPDA) and the International Niemann‐Pick Disease Registry (INPDR) developed and published comprehensive clinical management guidelines to support inclusive and standardized care pathways in Niemann‐Pick disease type C (NPC)—an ultra‐rare, autosomal recessive, neurovisceral lysosomal ...
Tarekegn Hiwot, Forbes D. Porter, Tatiana Bremova‐Ertl, Uma Ramaswami, Caroline Hastings, Bénédicte Héron, Justin Hopkin, Joella Melville, Hernan Amartino, Mireia del Toro, Federica Deodato, Fatih Ezgü, Paul Gissen, James B. Gibson, Can Ficicioglu, Roberto Giugliani, Orna Staretz‐Chacham, Frances Platt, Nathalie Guffon, Kristina Julich, Nikola Kresojević, Anna Lehman, Yann Nadjar, Susanne A. Schneider, Simon Jones, Eugen Mengel, Michel Tchan, Mark Walterfang, Ozlem Goker‐Alpan, Charlotte Dawson, Sandra Cowie, Toni Mathieson, Elizabeth Berry‐Kravis, Marc C. Patterson   +33 more
wiley   +1 more source

Glycopyrronium bromide for chronic obstructive pulmonary disease (Protocol)

, 2013
This is the protocol for a review and there is no abstract. The objectives are as follows: To critically appraise the efficacy and safety of glycopyrronium bromide, in terms of objective and subjective measures, in patients with ...
Bowman, Rayleen V., Eastment, Jacques G., Burke, Joseph P, Yang, Ian A., Fong, Kwun M.   +4 more
core   +1 more source

Development and Validation of the Japanese Version of the Hyperhidrosis Quality of Life Index

The Journal of Dermatology, Volume 53, Issue 2, Page 210-218, February 2026.
ABSTRACT Hyperhidrosis decreases an individual's quality of life (QOL). The Hyperhidrosis Quality of Life Index (HidroQoL) measures the impact of hyperhidrosis on QOL and has established reliability and validity. However, a Japanese version does not exist.
Sayaka Ogawa, Jun Tayama, Paul Kamudoni, Sam Salek, Peter Bernick, Masakazu Kobayashi, Seiko Nakamichi, Hiroyuki Murota   +7 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Deprescribing drugs with anticholinergic effects in older patients with increased risk of dementia in the multicomponent intervention study AgeWell.de

British Journal of Clinical Pharmacology, Volume 91, Issue 12, Page 3489-3500, December 2025.
Aim Drugs with anticholinergic effects are often considered as potentially inappropriate medications, especially for older patients, and deprescribing such drugs may improve cognitive function. The aim was to investigate the effectiveness of counselling on drug risks as part of a multimodal intervention to prevent cognitive decline. Methods The AgeWell.
Laura K. Lepenies, Hanna M. Seidling, Alexander Pabst, Melanie Luppa, Juliane Döhring, Martin Williamson, Thomas Frese, Jochen Gensichen, Wolfgang Hoffmann, Hanna Kaduszkiewicz, Hans‐Helmut König, Jochen René Thyrian, Birgitt Wiese, Steffi G. Riedel‐Heller, David Czock   +14 more
wiley   +1 more source

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD

Lung India, 2022
Background: The safety and efficacy of fixed-dose combination (FDC) of glycopyrronium bromide 12.5 μg/formoterol fumarate 12 μg (GB/FF) twice daily as dry powder inhalers (DPIs) compared to glycopyrronium 50 μg monotherapy (GLY) once daily as DPI in ...
Sundeep Salvi, Manish K Jain, Srikanth Krishnamurthy, Akash Balki, Rahul Kodgule, Monika Tandon, Sagar Bhagat, Sagar Panchal, Nishtha Khatri, Wen Wu, Amol Pendse, Saiprasad Patil, Hanmant Barkate   +12 more
doaj   +1 more source

Characterisation of the novel quinoline RCD405: Relaxant effects on cholinergic and histaminergic tone in human bronchi and small airways

British Journal of Pharmacology, Volume 182, Issue 17, Page 4122-4133, September 2025.
Abstract Background and Purpose Increased contractility of human airway smooth muscle (hASM) is a hallmark of asthma and chronic obstructive pulmonary disease (COPD). Developing new classes of bronchodilators has proved to be challenging because of efficacy and safety concerns.
Paola Rogliani, Clive Page, Francesco Facciolo, Mia Lundblad, Luigino Calzetta   +4 more
wiley   +1 more source

Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden

, 2015
OBJECTIVES: The objective of this study was to compare the cost effectiveness of once-daily Seebri Breezhaler(®) (glycopyrronium bromide) 50 µg with Spiriva(®) (tiotropium bromide) 18 µg in the maintenance treatment of chronic obstructive pulmonary ...
Goyal, Pankaj, Gruenberger, Jean-Bernard, Price, David, Ställberg, Björn,, Asukai, Yumi, Costa-Scharplatz, Madlaina   +5 more
core   +1 more source

Glycopyrronium 320 μg/mL in children and adolescents with severe sialorrhoea and neurodisabilities: An open‐label study extension of the SALIVA trial

Developmental Medicine &Child Neurology, Volume 67, Issue 8, Page 1085-1094, August 2025.
Plain language summary: https://onlinelibrary.wiley.com/doi/10.1111/dmcn.16268 Abstract Aims To test the long‐term efficacy, safety, and impact on quality of life (QoL) of an oral paediatric formulation of 320 μg/mL glycopyrronium in the 36‐week SALIVA (Sialanar plus orAl rehabiLitation against placebo plus oral rehabilitation for chIldren and ...
Pierre Fayoux, Mickael Dinomais, Helen Shaw, Frédéric Villain, Déborah Schwartz, Vincent Gautheron, Guy Letellier, Stéphane Auvin   +7 more
wiley   +1 more source